O6-Benzylguanine sodium
O6-Benzylguanine sodium is an orally active, blood-brain barrier-penetrant inhibitor of O6-methylguanine-DNA methyltransferase (MGMT/AGT). O6-Benzylguanine sodium modulates p53 and its downstream p21 and cyclins to induce cell cycle arrest and apoptosis, and on the other hand activates mTORC1/MAPK and other signaling pathways to induce cellular senescence by inhibiting intracellular MGMT. O6-Benzylguanine sodium is used in research related to various tumors, cellular senescence, and vascular smooth muscle dysfunction.
For research use only. We do not sell to patients.
- CAS No.: 100994-97-6
- Formula: C12H11N5NaO
- Molecular Weight:264.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
MGMT 0.1 μM (ED50) |
CDK1/cyclinB1 |
cdk2/cyclin A |
mTORC1 |
Caspase 9 |
In Vitro
O6-Benzylguanine (100 μM; 1-5 days) sodium inhibits cell growth, induces cellular senescence, and upregulates senescence-related markers such as p27, Bcl2, and MnSOD in rat aortic vascular smooth muscle cells (VSMCs)[3].
O6-Benzylguanine (50 μg/mL; 48 h) sodium downregulates MGMT and cyclin expression, upregulates p21 and pro-apoptotic protein expression, and induces apoptosis in human pancreatic cancer L3.6pl and PANC1 cells[2].
O6-Benzylguanine (up to 1000 μM; 30 min) sodium inactivates AGT in purified Escherichia coli Ada-C mutant protein and human AGT protein (with an ED50 of 0.1 μM when bound to DNA)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:L3.6pl and PANC1 cells
-
Concentration:50 μg/mL
-
Incubation Time:48 h
-
Result:Decreased the protein expressions of MGMT, cyclin B1, cyclin B2, cyclin A, and ki-67.
Increased the expression of p21, cytochrome C, caspase 9, and the cleavage of PARP1.
-
Cell Line:L3.6pl and PANC1 cells
-
Concentration:50 μg/mL
-
Incubation Time:48 h
-
Result:Reduced the mRNA levels of cyclin B1, cyclin B2, cyclin A, ki-67, and MGMT, and increased the mRNA levels of p21.
-
Cell Line:Rat aortic VSMCs
-
Concentration:100 μM
-
Incubation Time:1, 3, 5 days
-
Result:Increased the protein levels of p27, Bcl2, MnSOD, and pERK1/2, and decreased the levels of PCNA and αSMA.
-
Cell Line:Rat aortic VSMCs
-
Concentration:100 μM
-
Incubation Time:5 days
-
Result:Caused cells to become enlarged in morphology and displayed intense staining signals for γH2A.X.
In Vivo
O6-Benzylguanine (4 mg/kg; p.o.; once every 3 days; 7 weeks) sodium decreases the vasodilatory response of aortic smooth muscle to sodium nitroprusside and enhances its response to K+Cl− in healthy male Wistar rats[3].
O6-Benzylguanine sodium sensitizes human pancreatic tumor xenografts expressing AGT in athymic mice to the antitumor activity of BCNU (HY-13585) and Temozolomide (HY-17364)[1].
O6-Benzylguanine sodium reduces the maximum tolerated dose of BCNU in mice and dogs, indicating that it enhances the toxicity of BCNU to normal tissues[1].
O6-Benzylguanine sodium exhibits superior cerebrospinal fluid penetration compared to its analogs in adult male rhesus monkeys, supporting its use for brain tumor treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-nu (male, 8 to 12 weeks of age, orthotopic injection of human L3.6pl pancreatic cancer cells into the pancreas)[2]
-
Dosage:100 μg
-
Administration:i.p.; once daily Monday-Friday; 5 weeks
-
Result:Reduced median pancreatic tumor volume to 2419 mm3 (vs. 4596 mm3 in control mice).
Reduced median tumor weight to 1.53 g (vs. 2.96 g in control mice).
Decreased expression of MGMT, cyclin B1, cyclin B2, cyclin A, and the proliferation marker ki-67 in tumors.
Increased expression of p21 in tumors.
Increased tumor cell apoptosis (TUNEL-positive staining) compared to control mice.
-
Animal Model:Wistar rats (male, 12-week-old)[3]
-
Dosage:4 mg/kg
-
Administration:p.o.; every third day; 7 weeks
-
Result:Increased response to KCl in aortic rings.
Reduced smooth muscle relaxation response to the NO donor sodium nitrate in aortic rings.
Unchanged responses to phenylephrine and isoprenaline in aortic rings.
Chemical Information
-
CAS No. 100994-97-6
-
Molecular Weight 264.24
-
Formula C12H11N5NaO
-
SMILES
NC(N=C1OCC2=CC=CC=C2)=NC3=C1NC=N3.[Na]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
Purity & Documentation
References
[1]. Rabik CA, et al. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer treatment reviews. 2006 Jun;32(4):261-76. [Content Brief]
[2]. Konduri SD, et al. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Oct 01;15(19):6087-95. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)